Alnylam Pharmaceuticals (ALNY) Interest & Investment Income (2009 - 2026)

Alnylam Pharmaceuticals has reported Interest & Investment Income for 18 years, with the latest figure at $26.6 million in Q1 2026.

• For the quarter ending Q1 2026, Interest & Investment Income fell 7.24% year-over-year to $26.6 million; the trailing twelve-month figure through Mar 2026 stood at $109.4 million (down 9.61% YoY), and the FY2025 full-year result was $111.5 million, down 8.63% from the prior year.
• Interest & Investment Income for Q1 2026 stood at $26.6 million, roughly flat from $26.6 million in the prior quarter.
• The five-year high for Interest & Investment Income was $32.1 million in Q3 2024, with the low at $1.0 million in Q1 2022.
• Historically, Interest & Investment Income has averaged $22.4 million across 5 years, with a median of $26.6 million in 2025.
• Annual changes were most pronounced in 2022 — Interest & Investment Income soared 3375.56% — and 2025, when it declined 14.15%.
• Alnylam Pharmaceuticals' Interest & Investment Income stood at $14.1 million in 2022, then surged by 116.0% to $30.4 million in 2023, then climbed by 2.02% to $31.0 million in 2024, then retreated by 14.15% to $26.6 million in 2025, then declined by 0.12% to $26.6 million in 2026.
• The last three Interest & Investment Income figures came in at $26.6 million (Q1 2026), $26.6 million (Q4 2025), and $28.7 million (Q3 2025), per Business Quant data.